Navigation Links
Keryx Biopharmaceuticals' Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
Date:9/14/2009

e kidney, the five-year survival rate is 60 to 70 percent; but the survival rate is considerably lower after the cancer has metastasized to other parts of the body. Even with the recent approval of several biological therapies for the treatment of advanced metastatic RCC (VEGF inhibitors, sunitinib and sorafenib, and mTOR inhibitors everolimus and temsirolimus), the National Cancer Institute reports a rising incidence of RCC with incidence and mortality rates more than twice as high in men as in women. In 2009, an estimated 49,000 new cases of RCC and 11,000 deaths attributable to RCC are expected in the US.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in pa
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... TODAY, AEGATE, the leader in ... the appointment of Peter Fox as Chief ... and Partner Officer. Peter has served as ... acquisition by Oracle in 2011. Prior to ... and subsequently Convergys, a world renowned billing ...
(Date:12/19/2014)... , Dec. 19, 2014 You,re visiting ... checkup and cleaning when he or she says you ... probably heard before, you may have several questions and ... be relieved to know it,s nothing to worry about. ... patients, questions and alleviate any anxiety the public may ...
(Date:12/19/2014)... 2014 Breckenridge Pharmaceutical, Inc. announced today that ... Laboratories Pvt. Ltd. ( Hyderabad, India ) ... new ANDAs.  Under the terms of the agreement, MSN ... Breckenridge for the U.S. market, and Breckenridge will market ... MSN have agreed to develop an oral antibiotic with ...
Breaking Medicine Technology:Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Root Canals Have Become More Routine 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2
(Date:12/22/2014)... Physicians in China are most eagerly ... of non-Hodgkin’s lymphoma (NHL), according to a new report ... consulting firm. MabThera is the only biologic available to ... form of NHL. , According to Kantar Health’s report, ... of NHL in China has been growing and is ...
(Date:12/22/2014)... 2014 Give a loved one the ... of health and vitality. , For a limited time, ... anti-aging formulas in special Holiday Wellness gift packages at ... , Each bottle contains cutting-edge, proven nutritional support for ... as well as we age. , Joint ...
(Date:12/22/2014)... Austin, Texas (PRWEB) December 22, 2014 ... hustle and bustle of Black Friday shopping and opted ... publishing and marketing education company, for their 5th annual ... Marketer charged just $7 to attend the 5 ... sales that they promptly donated to support two Central ...
(Date:12/22/2014)... 22, 2014 NAPW honors ... Woman of the Year. She is recognized with this ... most recognized networking organization of professional women in the ... Association of Professional Women is a vibrant networking community ... , Ms. Kreider is passionate and committed to best ...
(Date:12/21/2014)... In this report, the global powered ... product, and application. The market, by power source, ... By product, the market covers the handpieces; power ... market is further subdivided into drills, saws, reamers, ... shavers, wire/pin drivers, and others. Moreover, the power ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... May 6 Volcano Corporation (Nasdaq: VOLC ... of products for the diagnosis and treatment of coronary ... be participating in the Bank of America and Merrill ... presentation by Scott Huennekens, president and chief executive officer, ...
... Incorporated has initiated a voluntary, nationwide recall of one lot ... healthcare professionals as an aid in the diagnosis of myocardial ... to reports of low recovery of quality control samples containing ... affected lot. Although there have been no reported issues ...
... HOUSTON - A newly discovered gene known as DEAR1 is ... local recurrence-free survival in early-onset breast cancer, a research team ... Anderson Cancer Center reports in the journal PLoS Medicine ... because so many young women have recurrences in the breast, ...
... The Mobile Massage Team ( www.mobilemassageteam.com ), a ... programs, promotional events, and special affairs, today announced that the ... Annual GlobalFit Worksite Wellness Summit ( http://www.globalfit.com/summit/ ... Down Town Club in Center City Philadelphia. Team members ...
... - Leadership in Fight Against Tobacco Recognized Nationally -WASHINGTON, May ... of Greenfield, Ind., has been named the National Youth Advocate ... her leadership in the fight against tobacco. Emily is being ... 6) with four regional winners and a group winner. (Logo: ...
... released today by Ernst Berndt and Mark Trusheim of ... that eliminating FDA,s preemption protection would decrease patients, access ... reduce medical device industry employment. The paper, ... Devices on Patients, Innovation and Jobs," comes as ...
Cached Medicine News:Health News:Volcano Corporation Presentation at Bank of America/Merrill Lynch Conference to be Webcast 2Health News:Biosite Incorporated Issues Voluntary, Nationwide Recall for Cardiac Marker Test 2Health News:Novel gene predicts local recurrence in early onset breast cancer 2Health News:Novel gene predicts local recurrence in early onset breast cancer 3Health News:Campaign for Tobacco-Free Kids Honors Emily Kile, Greenfield, IN, as National Youth Advocate of the Year 2Health News:Removing Medical Device Preemption Impacts Jobs, Health Care Costs, Patient Access 2
... TOPS is a support catheter which assists ... angioplasty or stenting. The spiral catheter offers ... with .014 to .018 steerable guidewires to ... occlusion is crossed, TOPS is withdrawn while ...
... are indicated for the removal ... thrombi from vessels in the ... also be used for temporary ... of fluids, and blood sampling. ...
Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system....
The new XMI catheter incorporates the best in catheter technology to ,provide exceptional handling characteristics comparable to todays balloon catheters and stent delivery systems....
Medicine Products: